# Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

> **NCT05460481** · PHASE2 · UNKNOWN · sponsor: **Hunan Cancer Hospital** · enrollment: 29 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Anlotinib Plus Penpulimab

## Key facts

- **NCT ID:** NCT05460481
- **Lead sponsor:** Hunan Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-12
- **Primary completion:** 2023-06
- **Final completion:** 2024-12
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2022-07-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05460481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05460481, "Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05460481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*